Hangzhou Innogate Pharma Co., Ltd.

Xiamen Biotime Biotechnology Co., Ltd.

Hangzhou Sanhua Research Institute Co., Ltd.

Shifeng Liu

Hancheng Zhang

Xiangyang Ye

Zhiyong Yu

Lin-Jie Huang

Junqi Dong

Ji Wang

Peng Chen

Li Li

Mei Wang

Yongqiang Shi

Xu Li

Wenting Chen

Wenqing Chen

Wei Pang

A compound represented by formula (I) and a pharmaceutical composition thereof. The compound represented by formula (I) can be used as an adenosine receptor inhibitor, in particular, A2A and/or A2B inhibitors, for example, can be used for preventing or treating diseases related to A2A and/or A2B activity or expression level.

Adenosine receptor antagonist

The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R. 

Highly active CSF1R inhibitor compound

The present application provides a pipeline adapter including a first connection block, a second connection block, a fastener and a seal ring. The first connection block is provided with a first channel and a first annular positioning groove disposed around the first channel. The second connection block is provided with a second channel communicating with the first channel and a second annular positioning platform fitting inside the first annular positioning groove. The second annular positioning platform is disposed around the second channel. The fastener connects the first connection block to the second connection block. The seal ring fits between the first annular positioning groove and the second annular positioning platform. The pipeline adapter is convenient to use, has a favorable sealing effect, and facilitates pipeline connection of a refrigeration system.

Pipeline adapter

A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described. 

Heterocyclic compound serving as FGFR4 inhibitor

The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts, hydrates, and solvates thereof. It also provides pharmaceutical compositions, preparation and utilities thereof in treating diseases and disorders including cancers. 

Heterocycles useful as anti-cancer agents

A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC. 

Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor

A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases. 

Compound containing tricyclic heteroaryl group

A heterocyclic compound is described, which is an inhibitor of FGFR (fibroblast growth factor receptor). Specifically, it is a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates. The definition of each group in the formula (I) is as described in the specification. The compound of the present invention has FGFR inhibitory activity and can be used for preventing or treating a disease associated with FGFR activity or expression. 

Heterocyclic compound used as FGFR inhibitor

A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosterics, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases. 

Provided are compounds of Formula (I) shown below using for treatment of diseases or disorders mediated by IDO and/or TDO, pharmaceutical compositions and methods of preparation thereof. 

Growing community of inventors

Zhejiang, China

Shifeng Liu